Literature DB >> 11805212

alpha(1A)-adrenoceptors mediate sympathetically evoked pupillary dilation in rats.

Yongxin Yu1, Michael C Koss.   

Abstract

Evidence suggests that in some species (cats, rabbits, and possibly humans) alpha-adrenoceptors in the iris dilator muscle are "atypical" in that they cannot be readily classified by conventional criteria. This study was undertaken in an attempt to characterize the alpha-adrenoceptor subtype(s) mediating sympathetically elicited mydriasis in rats. Frequency-response pupillary dilator curves were generated by stimulation of the preganglionic cervical sympathetic nerve (1-32 Hz) in pentobarbital-anesthetized rats. Evoked responses were inhibited by systemic administration of nonselective alpha-adrenergic antagonists, phentolamine (0.3-10 mg/kg) and phenoxybenzamine (0.03-1 mg/kg). The selective alpha(1)-adrenergic antagonist, prazosin (0.01-1 mg/kg), also was effective, although alpha(2)-adrenergic antagonism with rauwolscine (0.1-1 mg/kg) was not. alpha(1A)-Adrenoceptor-selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), as well as the alpha(1D)-adrenoceptor-selective antagonist 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1-3 mg/kg), were used to determine the subtype(s) involved. Evoked mydriasis was significantly antagonized by both WB-4101 and 5-methylurapidil but not by BMY-7378. These results suggest that, unlike some other species, adrenoceptors in the rat iris dilator mediating neurogenic mydriasis are "typical" and, in addition, can be characterized as being primarily of the alpha(1A)-adrenoceptor subtype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11805212     DOI: 10.1124/jpet.300.2.521

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits.

Authors:  Martin C Michel; Hiroko Okutsu; Yukiko Noguchi; Masanori Suzuki; Akiyoshi Ohtake; Hironori Yuyama; Hiroko Yanai-Inamura; Masashi Ukai; Mai Watanabe; Akiyoshi Someya; Masao Sasamata
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-18       Impact factor: 3.000

Review 2.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

3.  Alpha-blockers and intraoperative floppy iris syndrome: ophthalmic adverse events following cataract surgery.

Authors:  Zuhair K Al-Hussaini; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

4.  Melatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential.

Authors:  Eun-Joo Shin; Yoon Hee Chung; Hoang-Lan Thi Le; Ji Hoon Jeong; Duy-Khanh Dang; Yunsung Nam; Myung Bok Wie; Seung-Yeol Nah; Yo-Ichi Nabeshima; Toshitaka Nabeshima; Hyoung-Chun Kim
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-30       Impact factor: 5.176

Review 5.  Complications of cataract surgery in patients with BPH treated with alpha 1A-blockers.

Authors:  Slawomir Jan Teper; Dariusz Dobrowolski; Edward Wylegala
Journal:  Cent European J Urol       Date:  2011-06-02

6.  Phentolamine Mesylate Ophthalmic Solution Provides Lasting Pupil Modulation and Improves Near Visual Acuity in Presbyopic Glaucoma Patients in a Randomized Phase 2b Clinical Trial.

Authors:  Jay S Pepose; Paul J Hartman; Harvey B DuBiner; Marc A Abrams; Robert J Smyth-Medina; Sayoko E Moroi; Alan R Meyer; Mina P Sooch; Reda M Jaber; Konstantinos Charizanis; Seth A Klapman; Arin T Amin; Jonah E Yousif; Eliot S Lazar; Paul M Karpecki; Charles B Slonim; Marguerite B McDonald
Journal:  Clin Ophthalmol       Date:  2021-01-08

7.  A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances.

Authors:  Jay Pepose; Mitchell Brigell; Eliot Lazar; Curtis Heisel; Jonah Yousif; Kavon Rahmani; Ajay Kolli; Min Hwang; Cara Mitrano; Audrey Lazar; Konstantinos Charizanis; Mina Sooch; Marguerite McDonald
Journal:  BMC Ophthalmol       Date:  2022-10-08       Impact factor: 2.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.